Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Feb 17 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Sirolimus Tablets in two dosages. The tablets are used to prevent organ rejection in kidney transplant patients and to treat a rare lung disorder. The manufacturing will take place at the company's facility in Moraiya, and the drug had significant annual sales in the United States.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases